Last reviewed · How we verify

NCT05469568

Hybrid Rehabilitation Approach Through Group Exercise and Telerehabilitation in Patients With Multiple Sclerosis

Active, enrolled NA Last updated 29 September 2025
What this trial tests

NA trial testing Circuit training followed by telerehabilitation in Multiple Sclerosis in 50 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
15 July 2022
Primary endpoint
26 September 2025
30 December 2025

Quick facts

Lead sponsorBrno University Hospital
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment50
Start date15 July 2022
Primary completion26 September 2025
Estimated completion30 December 2025
Sites1 location across Czechia

Drugs / interventions tested

Conditions studied

Sponsor

Brno University Hospital

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to determine the benefits of outpatient group rehabilitation with subsequent telerehabilitation. The patient will participate in a 12-week circuit training, including training once a week in a group of six under the guidance of two physiotherapists. After the outpatient rehabilitation, the patient will gain access to a mobile application and will be asked to record all physical activities there.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Brno University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05469568.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing